IN8bio Terminates Prior Securities Agreement and Enters New One
IN8bio disclosed entry into a new material definitive agreement and simultaneous termination of a prior material definitive agreement in an 8-K filed with the SEC on June 1 2026. The changes alter the company's existing contractual financing or capital-raising arrangements and trigger standard Exhibit 99 disclosures that become part of the public record.
manilatimes.netIN8bio Inc. (NASDAQ: INAB) entered into a material definitive agreement while terminating a prior material definitive agreement, according to an 8-K filed with the Securities and Exchange Commission on June 1 2026.
The filing, submitted under Items 1.01, 1.02 and 9.01, identifies both the new counterparty arrangement and the terminated contract but does not publicly specify the dollar size of either agreement in the structured summary. Item 1.01 covers the entry into the new material definitive agreement while Item 1.02 records the termination of the earlier material definitive agreement.
Item 9.01 requires the company to furnish financial statements and exhibits related to the transactions.
Prior to the filing the company operated under the terms of the now-terminated agreement. The new agreement replaces it effective June 1 2026. The company must attach the relevant exhibits to the 8-K, making the specific terms available to investors and regulators as part of the official SEC record.
Downstream the filing starts the clock for any required follow-on disclosures if the agreements involve registration rights, warrants or other securities obligations. Market participants and the company's transfer agent or counsel must now operate under the new contract's notice, closing and compliance provisions.
If either agreement involved committed capital or a shelf-registration component, the termination ends those prior obligations while the new agreement may reset availability or reset covenants that the company must track in subsequent quarterly or current reports.
This marks the latest securities-related contract action by the clinical-stage biotechnology company, which maintains its Nasdaq listing and files periodic updates on clinical, regulatory and capital-structure developments. The 8-K itself constitutes the primary public record and requires no immediate shareholder vote unless the new agreement triggers separate proxy or registration-statement obligations under SEC rules.
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Related Stories
asiaone.comIranian Official: Tehran Manages Strait of Hormuz and Will Not Allow Maritime Blockade
Mohsen Rezaei stated that Iran controls the Strait of Hormuz and will not allow a maritime blockade to continue. Oil prices rose 8 percent on the day of the statements.
Substrate placeholder — needs reviewIran Suspends Indirect Talks With U.S. Amid Escalating Israel-Hezbollah Conflict in Lebanon
Iran has stopped all message exchange with the United States, including ongoing talks, in response to Israel's expanded offensive in Lebanon. The suspension was reported by Tasnim News Agency, which is affiliated with the Islamic Revolutionary Guard Corps according to the Jerusal…
Al JazeeraGreece Reviews Asylum Status for Syrians and Afghans After Conflicts End
Greek authorities began reviewing protection status for Syrians and Afghans in February after the end of Syria's civil war and the 2021 Taliban takeover. The reviews target men and coincide with new returns legislation.